Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety

Brittney S. Bates; Alice L. Rodriguez; Andrew S. Felts; Ryan D. Morrison; Daryl F. Venable; Anna L. Blobaum; Frank W. Byers; Kera P. Lawson; J. Scott Daniels; Colleen M. Niswender; Carrie K. Jones; P. Jeffrey Conn; Craig W. Lindsley; Kyle A. Emmitte

doi:10.1016/j.bmcl.2014.06.003

Discovery of VU0431316: A negative allosteric modulator of mGlu₅ with activity in a mouse model of anxiety

Brittney S. Bates, Alice L. Rodriguez, Andrew S. Felts, Ryan D. Morrison, Daryl F. Venable, Anna L. Blobaum, Frank W. Byers, Kera P. Lawson, J. Scott Daniels, Colleen M. Niswender, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley, Kyle A. Emmitte

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Abstract

Development of SAR in an aryl ether series of mGlu₅ NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu ₅ that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of VU0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu ₅ antagonists and other anxiolytics, produced dose proportional effects.

Original language	English
Pages (from-to)	3307-3314
Number of pages	8
Journal	Bioorganic and Medicinal Chemistry Letters
Volume	24
Issue number	15
DOIs	https://doi.org/10.1016/j.bmcl.2014.06.003
State	Published - 1 Aug 2014

Keywords

Allosteric modulator
Anxiety
CNS
Glutamate

Access to Document

10.1016/j.bmcl.2014.06.003

Fingerprint Dive into the research topics of 'Discovery of VU0431316: A negative allosteric modulator of mGlu<sub>5</sub> with activity in a mouse model of anxiety'. Together they form a unique fingerprint.

Cite this

Bates, B. S., Rodriguez, A. L., Felts, A. S., Morrison, R. D., Venable, D. F., Blobaum, A. L., Byers, F. W., Lawson, K. P., Daniels, J. S., Niswender, C. M., Jones, C. K., Conn, P. J., Lindsley, C. W., & Emmitte, K. A. (2014). Discovery of VU0431316: A negative allosteric modulator of mGlu₅ with activity in a mouse model of anxiety. Bioorganic and Medicinal Chemistry Letters, 24(15), 3307-3314. https://doi.org/10.1016/j.bmcl.2014.06.003

Bates, Brittney S. ; Rodriguez, Alice L. ; Felts, Andrew S. ; Morrison, Ryan D. ; Venable, Daryl F. ; Blobaum, Anna L. ; Byers, Frank W. ; Lawson, Kera P. ; Daniels, J. Scott ; Niswender, Colleen M. ; Jones, Carrie K. ; Conn, P. Jeffrey ; Lindsley, Craig W. ; Emmitte, Kyle A. / Discovery of VU0431316 : A negative allosteric modulator of mGlu₅ with activity in a mouse model of anxiety. In: Bioorganic and Medicinal Chemistry Letters. 2014 ; Vol. 24, No. 15. pp. 3307-3314.

@article{86aeec0d0b244c6286b74c776451ec92,

title = "Discovery of VU0431316: A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety",

abstract = "Development of SAR in an aryl ether series of mGlu5 NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu 5 that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of VU0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu 5 antagonists and other anxiolytics, produced dose proportional effects.",

keywords = "Allosteric modulator, Anxiety, CNS, Glutamate",

author = "Bates, {Brittney S.} and Rodriguez, {Alice L.} and Felts, {Andrew S.} and Morrison, {Ryan D.} and Venable, {Daryl F.} and Blobaum, {Anna L.} and Byers, {Frank W.} and Lawson, {Kera P.} and Daniels, {J. Scott} and Niswender, {Colleen M.} and Jones, {Carrie K.} and Conn, {P. Jeffrey} and Lindsley, {Craig W.} and Emmitte, {Kyle A.}",

year = "2014",

month = aug,

day = "1",

doi = "10.1016/j.bmcl.2014.06.003",

language = "English",

volume = "24",

pages = "3307--3314",

journal = "Bioorganic and Medicinal Chemistry Letters",

issn = "0960-894X",

publisher = "Elsevier Ltd",

number = "15",

}

Bates, BS, Rodriguez, AL, Felts, AS, Morrison, RD, Venable, DF, Blobaum, AL, Byers, FW, Lawson, KP, Daniels, JS, Niswender, CM, Jones, CK, Conn, PJ, Lindsley, CW & Emmitte, KA 2014, 'Discovery of VU0431316: A negative allosteric modulator of mGlu₅ with activity in a mouse model of anxiety', Bioorganic and Medicinal Chemistry Letters, vol. 24, no. 15, pp. 3307-3314. https://doi.org/10.1016/j.bmcl.2014.06.003

Discovery of VU0431316 : A negative allosteric modulator of mGlu₅ with activity in a mouse model of anxiety. / Bates, Brittney S.; Rodriguez, Alice L.; Felts, Andrew S.; Morrison, Ryan D.; Venable, Daryl F.; Blobaum, Anna L.; Byers, Frank W.; Lawson, Kera P.; Daniels, J. Scott; Niswender, Colleen M.; Jones, Carrie K.; Conn, P. Jeffrey; Lindsley, Craig W.; Emmitte, Kyle A.

In: Bioorganic and Medicinal Chemistry Letters, Vol. 24, No. 15, 01.08.2014, p. 3307-3314.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Discovery of VU0431316

T2 - A negative allosteric modulator of mGlu5 with activity in a mouse model of anxiety

AU - Bates, Brittney S.

AU - Rodriguez, Alice L.

AU - Felts, Andrew S.

AU - Morrison, Ryan D.

AU - Venable, Daryl F.

AU - Blobaum, Anna L.

AU - Byers, Frank W.

AU - Lawson, Kera P.

AU - Daniels, J. Scott

AU - Niswender, Colleen M.

AU - Jones, Carrie K.

AU - Conn, P. Jeffrey

AU - Lindsley, Craig W.

AU - Emmitte, Kyle A.

PY - 2014/8/1

Y1 - 2014/8/1

N2 - Development of SAR in an aryl ether series of mGlu5 NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu 5 that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of VU0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu 5 antagonists and other anxiolytics, produced dose proportional effects.

AB - Development of SAR in an aryl ether series of mGlu5 NAMs leading to the identification of pyrazine analog VU0431316 is described in this Letter. VU0431316 is a potent and selective non-competitive antagonist of mGlu 5 that binds at a known allosteric binding site. VU0431316 demonstrates an attractive DMPK profile, including moderate clearance and good bioavailability in rats. Intraperitoneal (IP) dosing of VU0431316 in a mouse marble burying model of anxiety, an assay known to be sensitive to mGlu 5 antagonists and other anxiolytics, produced dose proportional effects.

KW - Allosteric modulator

KW - Anxiety

KW - CNS

KW - Glutamate

UR - http://www.scopus.com/inward/record.url?scp=84904055106&partnerID=8YFLogxK

U2 - 10.1016/j.bmcl.2014.06.003

DO - 10.1016/j.bmcl.2014.06.003

M3 - Article

C2 - 24969015

AN - SCOPUS:84904055106

VL - 24

SP - 3307

EP - 3314

JO - Bioorganic and Medicinal Chemistry Letters

JF - Bioorganic and Medicinal Chemistry Letters

SN - 0960-894X

IS - 15